Search research articles
Contact Us
Filters
Showing results (161-170 of 259) with videos related to
Page
of 26
Sort By:
EMBO Molecular Medicine
|
March 12, 2021
Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling
Neetu Saxena, Eliana Beraldi, Ladan Fazli, et al.
Plos One
|
August 11, 2012
Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells
Jing Jiao, Antreas Hindoyan, Shunyou Wang, et al.
Molecular Cancer Research : MCR
|
January 8, 2025
Exploring B7-H4's Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Ning Kang, Hui Xue, Nelson K Y Wong, et al.
Journal of the National Cancer Institute
|
September 21, 2013
Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development
Qian Wang, Jessamy Tiffen, Charles G Bailey, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
July 31, 2015
Canadian guidelines for the management of small renal masses (SRM)
Michael A S Jewett, Ricardo Rendon, Louis Lacombe, et al.
Oncogene
|
April 10, 2025
Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer
Joy C Yang, Pengfei Xu, Shu Ning, et al.
Oncotarget
|
August 14, 2014
The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth
Yuh-Shyan Tsai, Chen-Li Lai, Chih-Ho Lai, et al.
Oncogene
|
January 3, 2023
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer
Joy C Yang, Pengfei Xu, Shu Ning, et al.
Future Oncology (London, England)
|
December 12, 2024
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
BJU International
|
February 21, 2007
Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography
Donald T T Yapp, Janet Woo, Aileen Kartono, et al.
Page
of 26
Search research articles
Search
Showing results (161-170 of 259) with videos related to
Sort By:
Page
of 26
EMBO Molecular Medicine
|
March 12, 2021
Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling
Neetu Saxena, Eliana Beraldi, Ladan Fazli, et al.
Plos One
|
August 11, 2012
Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells
Jing Jiao, Antreas Hindoyan, Shunyou Wang, et al.
Molecular Cancer Research : MCR
|
January 8, 2025
Exploring B7-H4's Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Ning Kang, Hui Xue, Nelson K Y Wong, et al.
Journal of the National Cancer Institute
|
September 21, 2013
Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development
Qian Wang, Jessamy Tiffen, Charles G Bailey, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
July 31, 2015
Canadian guidelines for the management of small renal masses (SRM)
Michael A S Jewett, Ricardo Rendon, Louis Lacombe, et al.
Oncogene
|
April 10, 2025
Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer
Joy C Yang, Pengfei Xu, Shu Ning, et al.
Oncotarget
|
August 14, 2014
The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth
Yuh-Shyan Tsai, Chen-Li Lai, Chih-Ho Lai, et al.
Oncogene
|
January 3, 2023
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer
Joy C Yang, Pengfei Xu, Shu Ning, et al.
Future Oncology (London, England)
|
December 12, 2024
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
BJU International
|
February 21, 2007
Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography
Donald T T Yapp, Janet Woo, Aileen Kartono, et al.
Page
of 26